One day after the U.S. Food and Drug Administration approved Shringrix to prevent shingles (herpes zoster) in patients 50 years and older, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended the use of Shingrix to prevent shingles over Merck’s Zostavax vaccine that is less effective, but was the only shingles vaccine on the market for over a decade. ACIP also recommended that adults who have received the older vaccine get the new one. [ read more ]

Study Shows Impact of Age and Pre-Existing Influenza Immune Responses in Older and Younger Adults

In an effort to understand how current influenza vaccines are influenced by pre-existing immunity in people of different ages, researchers vaccinated volunteers ages 18 years to 85 years with split, inactivated Fluzone influenza vaccine in four consecutive seasons from 2013 to 2016, and assessed the impact of repeated vaccination on breadth and durability of antibodies as a result of vaccine strain changes. They found that, overall, both younger and older people have the ability to mount a breadth of immune responses following influenza vaccination. [ read more ]

Subcutaneous Immune Globulin Is Well-Tolerated and Effective in Mild to Moderate Exacerbations of Myasthenia Gravis

From CSL Behring

From Roche

From Shire